Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,879 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS).
Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG; VHICS Study Team. Wyles DL, et al. Among authors: kang m. Open Forum Infect Dis. 2018 Jun 4;5(6):ofy103. doi: 10.1093/ofid/ofy103. eCollection 2018 Jun. Open Forum Infect Dis. 2018. PMID: 29977962 Free PMC article.
Continued Low Rates of Hepatitis C Virus (HCV) Recurrence in HCV/HIV- and HCV-Infected Participants Who Achieved Sustained Virologic Response After Direct-Acting Antiviral Treatment: Final Results From the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS).
Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG. Wyles DL, et al. Among authors: kang m. Open Forum Infect Dis. 2021 Oct 14;8(12):ofab511. doi: 10.1093/ofid/ofab511. eCollection 2021 Dec. Open Forum Infect Dis. 2021. PMID: 34926713 Free PMC article.
Immunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Naïve People With Human Immunodeficiency Virus.
Marks KM, Kang M, Umbleja T, Avihingsanon A, Sugandhavesa P, Cox AL, Vigil K, Perazzo H, Price JC, Katsidzira L, Vernon C, Alston-Smith B, Sherman KE; ACTG 5379 Study Team. Marks KM, et al. Among authors: kang m. Clin Infect Dis. 2023 Aug 14;77(3):414-418. doi: 10.1093/cid/ciad201. Clin Infect Dis. 2023. PMID: 37017075 Free PMC article.
Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial.
Amorosa VK, Luetkemeyer A, Kang M, Johnson VA, Umbleja T, Haas DW, Yesmin S, Bardin MC, Chung RT, Alston-Smith B, Tebas P, Peters MG. Amorosa VK, et al. Among authors: kang m. HIV Clin Trials. 2013 Nov-Dec;14(6):274-83. doi: 10.1310/hct1406-274. HIV Clin Trials. 2013. PMID: 24334180 Free PMC article. Clinical Trial.
Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin.
Petersen T, Lee YJ, Osinusi A, Amorosa VK, Wang C, Kang M, Matining R, Zhang X, Dou D, Umbleja T, Kottilil S, Peters MG. Petersen T, et al. Among authors: kang m. AIDS Res Hum Retroviruses. 2016 Jul;32(7):660-7. doi: 10.1089/aid.2015.0236. Epub 2016 Mar 14. AIDS Res Hum Retroviruses. 2016. PMID: 26974581 Free PMC article. Clinical Trial.
Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral therapy.
Hawkins C, Kang M, Bhattacharya D, Cloherty G, Kuhns M, Matining R, Thio C, Samaneka W, Chinula L, Mulinda N, Badal-Faesen S, Sugandhavesa P, Lama J, Gaseitsiwe S, Holzmayer V, Anderson M, Murphy R, Peters M. Hawkins C, et al. Among authors: kang m. AIDS. 2022 Jun 1;36(7):975-984. doi: 10.1097/QAD.0000000000003193. Epub 2022 Feb 14. AIDS. 2022. PMID: 35165216 Free PMC article.
Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study.
Sulkowski MS, Kang M, Matining R, Wyles D, Johnson VA, Morse GD, Amorosa V, Bhattacharya D, Coughlin K, Wong-Staal F, Glesby MJ; AIDS Clinical Trials Group A5277 Protocol Team. Sulkowski MS, et al. Among authors: kang m. J Infect Dis. 2014 Mar 1;209(5):658-67. doi: 10.1093/infdis/jit503. Epub 2013 Sep 16. J Infect Dis. 2014. PMID: 24041792 Free PMC article. Clinical Trial.
Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220.
Overton ET, Kang M, Peters MG, Umbleja T, Alston-Smith BL, Bastow B, Demarco-Shaw D, Koziel MJ, Mong-Kryspin L, Sprenger HL, Yu JY, Aberg JA. Overton ET, et al. Among authors: kang m. Vaccine. 2010 Aug 2;28(34):5597-604. doi: 10.1016/j.vaccine.2010.06.030. Epub 2010 Jun 23. Vaccine. 2010. PMID: 20600512 Free PMC article. Clinical Trial.
9,879 results